Please ensure Javascript is enabled for purposes of website accessibility

Why Replimune Stock Is Soaring Today

By Keith Speights – Oct 15, 2020 at 10:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company plans to present encouraging early-stage clinical data at a major conference next month.

What happened

Shares of Replimune Group (REPL 3.91%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The big jump resulted from the company's announcement that it will present encouraging data from two early-stage clinical studies evaluating experimental immunotherapies RP1 and RP2 at the Society for Immunotherapy of Cancer (SITC) annual meeting in November.

So what

Positive clinical news is exactly what a clinical-stage biotech stock like Replimune needs to get investors excited. The company's scheduled virtual poster presentations at SITC are indeed good news.

Scientist typing on a laptop with another scientist in the background looking through a microscope

Image source: Getty Images.

Replimune's press release about the upcoming SITC meeting included some details from the abstracts to be presented. The company said that half of the patients receiving RP2 as a monotherapy in a phase 1 study targeting solid tumors "have ongoing partial responses." That means these study participants are experiencing significant tumor reduction. 

In addition, Replimune plans to present data from a phase 1/2 study of a combination of RP1 and Bristol Myers Squibb's Opdivo in treating several types of cancer. The biotech's press release stated that this combo continues "to be well tolerated, with continuing promising anti-tumor activity in patients with skin cancers."

While encouraging data for RP1 and RP2 are good news for Replimune, it's still very early. Both studies are still ongoing.

Now what

Investors will want to keep their eyes on further updates from Replimune on these clinical trials. The company is also enrolling patients in a phase 2 study of RP1 in combination with cancer immunotherapy Libtayo in treating cutaneous squamous cell carcinoma, the second most common type of skin cancer. In addition, Replimune plans to begin a phase 1 study evaluating another candidate, RP3, as a monotherapy and in combination with an anti-PD-1 therapy this year.

Keith Speights owns shares of Bristol Myers Squibb. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Replimune Group, Inc. Stock Quote
Replimune Group, Inc.
REPL
$17.27 (3.91%) $0.65
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$71.09 (-0.86%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.